- A 75-year-old male with stable NYHA Class III heart failure (ejection fraction 30%) develops acute osteoarthritis pain in his knee. His creatinine is 1.5 mg/dL. His provider considers prescribing a short course of naproxen. What is the primary pathophysiologic reason this class of medication is relatively contraindicated?
Answer: Inhibition of renal prostaglandin synthesis, leading to sodium and water retention and potential cardiac decompensation.
In heart failure, renal perfusion is maintained in part by vasodilatory prostaglandins. Non-steroidal anti-inflammatory drugs (NSAIDs) like naproxen inhibit cyclooxygenase (COX) enzymes, thereby decreasing prostaglandin synthesis. This leads to afferent arteriolar vasoconstriction in the kidney, reduced renal blood flow, and increased sodium and water retention. The resulting volume expansion can increase preload and afterload, precipitating an acute exacerbation of heart failure. This hemodynamic effect is the primary contraindication in this patient population.
- A 19-year-old female with severe, refractory nodulocystic acne is a candidate for oral isotretinoin. Which of the following is an absolute requirement based on the primary contraindication for this drug in this patient?
Answer: Enrollment in the iPLEDGE risk management program due to the extreme risk of severe birth defects.
Isotretinoin is one of the most potent human teratogens in clinical use, causing severe, life-threatening birth defects. This risk is the primary contraindication in females of childbearing potential. To mitigate this risk, the FDA mandates the iPLEDGE program. This strict risk management program requires documentation of two forms of effective contraception, two negative pregnancy tests before starting, and monthly negative pregnancy tests before each new prescription can be dispensed. While other side effects like hepatotoxicity exist, the teratogenic risk is the reason for these unparalleled restrictions.
- A 30-year-old male with treatment-resistant schizophrenia has failed adequate trials of two other antipsychotics. His psychiatrist recommends starting clozapine. When counseling about the risks, what is the most accurate statement regarding the primary risk that contraindicates its use without specific hematological monitoring?
Answer: There is a risk of severe neutropenia (agranulocytosis), which mandates enrollment in a registry for ANC monitoring.
Clozapine carries a boxed warning for severe neutropenia (agranulocytosis), which occurs in approximately 1% of patients and can be fatal if undetected. Because of this risk, its use is contraindicated unless the patient can be enrolled in a mandatory registry that requires a baseline absolute neutrophil count (ANC) and regular, frequent ANC monitoring throughout treatment and for a period after discontinuation. While risks like myocarditis and metabolic syndrome are significant, the risk of agranulocytosis is the reason for the unique and stringent hematological monitoring requirement.
- A 22-year-old female is diagnosed with bipolar I disorder and also has a history of generalized tonic-clonic seizures. Her physician suggests initiating divalproex sodium. Which factor presents the most compelling reason to consider alternative agents before starting this medication?
Answer: The high teratogenic potential, including a significant risk of neural tube defects if pregnancy occurs.
Valproic acid and its derivatives (divalproex sodium) are potent human teratogens, associated with a 10% risk of major congenital malformations, including a 1-2% risk of neural tube defects. For a female of childbearing potential, this risk is a primary consideration and often a relative contraindication, especially when other effective medications with lower teratogenic risk (e.g., lamotrigine, certain atypical antipsychotics) are available. While other risks like pancreatitis and weight gain exist, the teratogenic risk is paramount in this patient population.
- A 70-year-old male with HFrEF is managed with lisinopril and carvedilol. His eGFR is 28 mL/min/1.73m² and his baseline serum potassium is 5.1 mEq/L. A cardiologist suggests adding spironolactone 12.5 mg daily. Which factor is the strongest contraindication to this therapeutic addition?
Answer: The significant cumulative risk of life-threatening hyperkalemia from multiple concurrent risk factors.
The use of spironolactone is contraindicated in this patient due to the high risk of severe hyperkalemia. He has three major risk factors: 1) advanced chronic kidney disease (eGFR < 30), which impairs potassium excretion; 2) concurrent use of an ACE inhibitor (lisinopril), which also increases potassium; and 3) a baseline potassium at the upper limit of normal. Adding a mineralocorticoid receptor antagonist (spironolactone), which blocks aldosterone's effect of potassium excretion, would very likely lead to dangerous or fatal hyperkalemia. Clinical trials establishing the benefit of spironolactone in heart failure generally excluded patients with this degree of renal impairment or hyperkalemia.
- A 60-year-old male, maintained on sertraline 100 mg daily for depression, is undergoing a parathyroidectomy. During the procedure, the surgeon plans to use intravenous methylene blue to identify the parathyroid glands. The anesthesiologist correctly intervenes, citing a contraindication. What is the basis for this concern?
Answer: Methylene blue is a potent, reversible monoamine oxidase inhibitor (MAOI) that is contraindicated with SSRIs due to high risk of serotonin syndrome.
This is a critical, often overlooked contraindication. Methylene blue, even at doses used for visualization or treating methemoglobinemia, is a potent reversible inhibitor of monoamine oxidase-A (MAO-A). Co-administration with a serotonergic drug like an SSRI (sertraline) blocks the two primary removal pathways for serotonin (reuptake and metabolism), leading to a high risk of severe, life-threatening serotonin syndrome. This combination is absolutely contraindicated.
- A 55-year-old female with a history of a myocardial infarction is being considered for beta-blocker therapy. She also has moderate persistent asthma, which is well-controlled on an inhaled corticosteroid and a long-acting beta-agonist. Which statement best guides the risk-benefit analysis for initiating a beta-blocker?
Answer: A cardioselective beta-1 blocker, such as metoprolol succinate, may be cautiously initiated at a low dose with close monitoring.
While non-selective beta-blockers (e.g., propranolol) are contraindicated in patients with reactive airway disease due to their antagonism of beta-2 receptors in the lungs, cardioselective beta-1 blockers (e.g., metoprolol, atenolol) have less effect on these receptors. In a patient with a compelling indication like a post-myocardial infarction status, the benefits of a cardioselective beta-blocker often outweigh the risks. The appropriate approach is to start with a low dose, monitor for any worsening of respiratory symptoms, and titrate slowly.
- A 55-year-old female requests treatment for toenail onychomycosis. Her medical history is significant for chronic hepatitis C infection with evidence of moderate hepatic fibrosis, though her recent liver function tests are within normal limits. Her provider is considering a 12-week course of oral terbinafine. What is the most important risk-benefit consideration?
Answer: Terbinafine is contraindicated in patients with chronic or active liver disease due to the risk of precipitating severe hepatotoxicity.
Oral terbinafine carries a warning for rare but serious cases of hepatotoxicity, including liver failure and death. Because of this, it is contraindicated by the manufacturer for patients with pre-existing chronic or active liver disease. While the patient's LFTs may be normal at baseline, the underlying fibrotic liver has reduced functional reserve, placing her at higher risk. The risk-benefit analysis does not favor using a potentially hepatotoxic drug for a non-life-threatening condition like onychomycosis in such a patient.
- A 29-year-old woman at 14 weeks gestation presents for a routine prenatal visit. Her blood pressure is 155/95 mmHg. Her medical history is significant for essential hypertension, for which she has been taking lisinopril 10 mg daily. Which of the following is the most critical reason to discontinue lisinopril in this patient?
Answer: The established risk of major congenital malformations and fetal renal agenesis when used in the second and third trimesters.
ACE inhibitors like lisinopril are contraindicated in pregnancy, particularly during the second and third trimesters, due to their established teratogenicity. They carry a boxed warning for fetal toxicity, including renal dysfunction, oligohydramnios, and skull hypoplasia. This risk to the fetus is the most critical and absolute reason for discontinuation.
- A newly diagnosed 41-year-old patient with HIV is being evaluated for an initial antiretroviral therapy (ART) regimen that includes abacavir. Which of the following evaluations is mandatory before prescribing this agent to assess for a contraindication?
Answer: HLA-B*5701 allele testing to prevent a potentially fatal hypersensitivity reaction.
Abacavir is associated with a multi-organ, potentially fatal hypersensitivity reaction (HSR) in about 5-8% of patients. This reaction is strongly linked to the presence of the human leukocyte antigen (HLA)-B*5701 allele. Screening for this allele before initiating abacavir is now the standard of care. If the test is positive, abacavir is permanently contraindicated for that patient. This pharmacogenomic testing has dramatically reduced the incidence of abacavir HSR.
- A 32-year-old G2P1 woman at 30 weeks gestation presents in preterm labor. Her medical history is significant for poorly controlled type 1 diabetes mellitus with recent episodes of hyperglycemia. The obstetrician is deciding on a tocolytic agent to suppress contractions. Which of the following agents is relatively contraindicated due to this patient's specific comorbidity?
Answer: Terbutaline
Terbutaline is a beta-2 adrenergic agonist. Stimulation of beta-2 receptors leads to glycogenolysis and gluconeogenesis in the liver and decreased glucose uptake by peripheral tissues, all of which result in hyperglycemia. In a patient with poorly controlled type 1 diabetes, this effect can be profound, potentially worsening her hyperglycemia and even precipitating diabetic ketoacidosis (DKA). Therefore, beta-2 agonists are relatively contraindicated as tocolytics in patients with diabetes. Other agents like nifedipine or magnesium sulfate do not have this direct hyperglycemic effect.
- A 62-year-old male with mixed hyperlipidemia is treated with atorvastatin 40 mg daily. Despite this, his triglycerides remain elevated at 450 mg/dL. The provider considers adding a fibrate. Which of the following represents the most significant contraindication or risk to evaluate before initiating combination therapy?
Answer: A significant increase in the risk of severe myopathy and rhabdomyolysis, particularly with gemfibrozil.
Both statins and fibrates can cause myopathy independently. When used in combination, this risk is significantly increased. The mechanism involves complex pharmacokinetic and pharmacodynamic interactions. Gemfibrozil, in particular, inhibits the glucuronidation of statins, increasing their systemic concentration and risk of toxicity. Fenofibrate is generally considered a safer option if combination therapy is deemed necessary, but the risk of myopathy and rhabdomyolysis remains the most critical safety concern to address.
- A 34-year-old female with major depressive disorder, stable on escitalopram 20 mg daily, presents with frequent debilitating migraines. A provider suggests initiating sumatriptan for abortive therapy. Which statement best characterizes the risk-benefit assessment for this combination?
Answer: The combination can be used cautiously with patient education on the signs of serotonin syndrome, as the absolute risk is low.
Both SSRIs (escitalopram) and triptans (sumatriptan) are serotonergic agents. The FDA has issued a warning about a potential increased risk of serotonin syndrome with concomitant use. However, large observational studies suggest the absolute risk is very low. In clinical practice, the combination is frequently used because the benefit of treating debilitating migraines often outweighs this small risk. The appropriate management is not to declare it an absolute contraindication, but to proceed with caution and educate the patient to recognize and report symptoms of serotonin syndrome (e.g., agitation, confusion, tachycardia, tremor, hyperthermia).
- A 48-year-old patient being treated for refractory depression with phenelzine reports significant mood improvement. During a follow-up visit, he mentions he is looking forward to a celebration dinner at a restaurant known for its aged cheeses, cured sausages, and red wine. Which of the following is the most critical contraindication to discuss with this patient?
Answer: These foods must be avoided as they contain high levels of tyramine, which can precipitate a hypertensive crisis.
Phenelzine is an irreversible monoamine oxidase inhibitor (MAOI). MAO-A in the gut wall and liver is responsible for breaking down dietary pressor amines like tyramine. When this enzyme is inhibited, ingested tyramine is absorbed systemically, causing a massive release of norepinephrine from sympathetic nerve terminals. This can lead to a sudden, severe, and potentially fatal hypertensive crisis. Aged cheeses, cured meats, and certain alcoholic beverages are rich in tyramine and are strictly contraindicated for patients on MAOI therapy.
- A 66-year-old male with stable angina pectoris, treated with isosorbide mononitrate, asks his physician for a prescription for sildenafil for erectile dysfunction. What is the absolute contraindication to using these medications concurrently?
Answer: Synergistic potentiation of vasodilation via the nitric oxide-cGMP pathway, leading to severe hypotension.
Organic nitrates (like isosorbide mononitrate) work by increasing the production of cyclic guanosine monophosphate (cGMP), which causes vasodilation. Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor, which works by preventing the breakdown of cGMP. When used together, the accumulation of cGMP is profound and synergistic, leading to widespread, severe vasodilation and a precipitous drop in blood pressure. This can cause syncope, ischemia, and even death, and is an absolute contraindication.
- A 72-year-old male on long-term warfarin therapy for atrial fibrillation has maintained a stable INR of 2.5. He develops community-acquired pneumonia and is prescribed a 7-day course of trimethoprim-sulfamethoxazole (TMP-SMX). What is the primary safety concern that necessitates immediate intervention?
Answer: A significant increase in INR and risk of major bleeding due to potent CYP2C9 inhibition by the antibiotic.
Trimethoprim-sulfamethoxazole is a potent inhibitor of the cytochrome P450 enzyme CYP2C9, which is the primary enzyme responsible for metabolizing the more potent S-enantiomer of warfarin. Inhibition of this enzyme leads to decreased warfarin clearance, a subsequent sharp increase in INR, and a significantly elevated risk of life-threatening bleeding. This interaction is a classic, high-risk contraindication requiring immediate management, such as selecting an alternative antibiotic or making aggressive adjustments to the warfarin dose with close INR monitoring.
- A 58-year-old male with newly diagnosed essential hypertension also has a history of gout, with his last flare being over a year ago. His baseline serum uric acid is 7.5 mg/dL. The provider suggests starting hydrochlorothiazide. Which statement is most accurate regarding this choice?
Answer: This diuretic is relatively contraindicated as it can decrease the renal excretion of uric acid and precipitate a gout attack.
Thiazide diuretics like hydrochlorothiazide are known to cause hyperuricemia. They compete with uric acid for secretion at the organic acid transporter in the proximal tubule of the kidney, leading to decreased uric acid excretion. In a patient with a history of gout and pre-existing borderline-high uric acid levels, initiating a thiazide diuretic poses a significant risk of precipitating an acute gouty flare. This makes it a relative contraindication, and other antihypertensive classes (e.g., ARBs like losartan, which is uricosuric, or calcium channel blockers) are often preferred.
- An 8-year-old boy presents with a complicated urinary tract infection and pyelonephritis caused by a multidrug-resistant Pseudomonas aeruginosa. The only effective oral antibiotic identified by susceptibility testing is ciprofloxacin. What is the most accurate risk-benefit assessment for using ciprofloxacin in this child?
Answer: Use is justified as the benefit of treating a serious infection outweighs the potential, but typically reversible, risk of arthropathy.
When you encounter pediatric antibiotic questions, you need to weigh the severity of infection against age-specific drug risks. This scenario presents a serious, life-threatening infection with limited treatment options, making risk-benefit analysis crucial.
Ciprofloxacin use in this case is justified because the child has a severe, multidrug-resistant infection where ciprofloxacin is the only effective oral option. While fluoroquinolones do carry arthropathy risks in children, these effects are typically reversible, and the benefit of treating a potentially fatal pyelonephritis outweighs this risk. The FDA allows fluoroquinolone use in children when benefits exceed risks.
Let's examine why the other options are incorrect. Choice A is too absolute—fluoroquinolones aren't completely contraindicated in children under 18. They're discouraged as first-line agents, but can be used when necessary, and arthropathy is usually reversible, not irreversible. Choice B confuses ciprofloxacin with aspirin. Reye's syndrome is associated with salicylate use during viral illnesses, not fluoroquinolones. Choice C incorrectly attributes tooth discoloration to ciprofloxacin—this is actually a side effect of tetracyclines, not fluoroquinolones.
Remember this key principle: pediatric antibiotic contraindications are rarely absolute. When you see "multidrug-resistant" infections with limited treatment options, the severity of untreated infection usually outweighs potential drug risks. Focus on matching the correct side effect profile to each antibiotic class—fluoroquinolones cause arthropathy, tetracyclines cause tooth discoloration, and salicylates (not fluoroquinolones) are linked to Reye's syndrome.
- An 80-year-old female with recurrent, symptomatic atrial fibrillation is being considered for long-term amiodarone therapy. She has a history of moderate COPD and a thyroid nodule of unknown significance. Which pre-existing conditions represent the most significant potential contraindications that must be thoroughly evaluated before initiation?
Answer: Pre-existing severe pulmonary disease and current thyroid dysfunction.
When evaluating any patient for amiodarone therapy, you must carefully assess for conditions that could be severely exacerbated by this drug's unique toxicity profile. Amiodarone has two major organ systems where serious, potentially life-threatening complications occur: the lungs and thyroid gland.
Amiodarone causes pulmonary toxicity in 5-15% of patients, presenting as pneumonitis or fibrosis that can be fatal. In patients with pre-existing severe pulmonary disease like advanced COPD, the respiratory reserve is already compromised, making any additional lung injury potentially catastrophic. Additionally, amiodarone contains iodine and affects thyroid function in multiple ways, causing both hyperthyroidism and hypothyroidism. In a patient with an existing thyroid nodule of unknown significance, amiodarone could trigger dangerous thyrotoxicosis or mask underlying thyroid pathology.
Choice A describes relatively minor concerns - lens deposits occur in most patients but rarely affect vision, and mild kidney disease doesn't significantly alter amiodarone metabolism. Choice B lists side effects that, while bothersome, aren't life-threatening contraindications. Choice C mentions drug interactions, but neither atorvastatin nor metoprolol represents a major contraindication to amiodarone use.
For pharmacology exams, remember that amiodarone questions often test knowledge of its "big three" toxicities: pulmonary, thyroid, and hepatic. Always look for answer choices that highlight pre-existing lung or thyroid disease, as these represent the most serious relative contraindications requiring extensive pre-treatment evaluation and ongoing monitoring.
- A 68-year-old male with type 2 diabetes, managed with metformin, is scheduled for a cardiac catheterization with iodinated contrast media. His most recent estimated glomerular filtration rate (eGFR) is 45 mL/min/1.73m². Which course of action represents the best risk-benefit decision regarding his metformin therapy?
Answer: Withhold metformin before the procedure and for 48 hours after, re-evaluating renal function before restarting.
The administration of iodinated contrast media can cause a temporary decline in renal function. In patients taking metformin with a pre-existing eGFR between 30-60 mL/min/1.73m², this creates a risk of metformin accumulation and subsequent lactic acidosis, a rare but life-threatening condition. Standard guidelines recommend withholding metformin at the time of or prior to the procedure, withholding it for 48 hours after, and restarting only after renal function has been re-evaluated and is not acutely worsened.
